SCHEMBL4124342

SCHEMBL4124342

COc1c(C)cccc1C(=O)c1cc(Cl)ccc1NC(=O)C(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.52
RAB9A P51151 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
POLB P06746 2/20 0.46
HPGD P15428 2/20 0.46
TSHR P16473 1/20 0.46
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5520431 0.90 MEN1 (0.49) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4123840 0.88 KMT2A (0.47) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4116756 0.87 TMPRSS4 (0.47) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4115436 0.85 MEN1 (0.49) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4131697 0.85 CNR2 (0.46) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL13776154 0.83 MEN1 (0.45) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL14146466 0.81 MEN1 (0.52) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL13776046 0.80 SMN1; SMN2 (0.52) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4109319 0.80 SMN1; SMN2 (0.48) MAPTRAB9AMEN1KMT2AALDH1A1
SCHEMBL4124495 0.80 MEN1 (0.47) MAPTRAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR MAPT 4428/4885RAB9A 4041/4885MEN1 2041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.